Business Wire

FL-ELEVATE-PRIZE-FNDTN

10.3.2021 15:02:05 CET | Business Wire | Press release

Share
Elevate Prize Foundation Launches Application for $5M Elevate Prize

The Elevate Prize Foundation is pleased to announce the launch of its second year of the Elevate Prize, which will commit $5 million in funding and services to 10 prize winners. The Foundation is searching for social impact leaders globally who are tackling the most pressing challenges of our time, with the most innovative and effective solutions.

Founders and CEOs of nonprofits and public charities worldwide are welcome to apply to win one of 10 annual Elevate Prizes. New this year is a simplified, two-phase application, making it significantly easier for nonprofit leaders to apply for the Prize. Phase 1, now open to all applicants, includes a shortened written application, while Phase 2 will include a more robust set of questions, released only to select applicants this summer.

The Elevate Prize Foundation, founded in 2019 by entrepreneur and philanthropist Joseph Deitch , is dedicated to giving unsung social entrepreneurs the necessary resources to scale their impact, and to ultimately help inspire and awaken the hero in all of us. The Foundation awarded its inaugural class of 10 winners in October 2020.

Each winner of this year’s Elevate Prize will receive:

  • MONEY . A minimum of $300,000 (USD) shared between winners and their nonprofit organizations, so they can collectively drive change.
  • AMPLIFICATION . Our strategic marketing and media expertise can take winners to the next level. Be a social impact influencer. Find fans. Build a platform. Think bigger. Do great things. Change the world.
  • MENTORSHIP . Our network of partners, executives and decision-makers offer the kind of professional development and business guidance money can’t buy.
  • CONNECTIONS . Each cohort is a radically diverse group of people leading innovative organizations. As a member of this cohort, winners will have the opportunity to learn from each other, create shared experiences, and build lasting relationships.
  • SUPPORT . We take the time to thoroughly understand winners’ needs as an individual and organization, and then create a tailored program that will help each winner reach their goals and beyond.

“The Elevate Prize remains committed to finding a radically diverse group of innovative problem solvers, and investing unconventional and personalized resources that bring greater visibility to them as leaders and the vital work they do. We make good famous,” said Carolina García Jayaram, executive director, Elevate Prize Foundation.

The Foundation is proud to partner with MIT Solve on this year’s Elevate Prize. As an extension of its partnership, the Foundation will commit one of its 10 Prizes to MIT Solve’s first US Challenge on Antiracist Technology. The Elevate Prize for Antiracist Technology is open to nonprofit leaders who are helping to create an antiracist and equitable future in the U.S. This exemplar leader will take part in both the MIT Solver program and the Elevate Prize program and receive ongoing support from both organizations.

The application process for the Prize begins today at www.elevateprize.org/apply and applicants can submit up until the May 5 deadline. Following this deadline, select applicants will be invited to complete Phase 2 of the application. Winners will be announced in October 2021.

About the Elevate Prize Foundation

Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, the Elevate Prize Foundation aims to elevate humanity on a global scale by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize – a search for innovators and activists that culminates with the selection of 10 leaders to receive funding and guidance to amplify their work. These changemakers are working to solve the world’s problems within healthcare, the environment, poverty, inequality, the arts, and more. Elevate Prize winners embark on a two-year program fueled by access to top scholars and industry leaders who guide and support them in scaling their impact. Together, Prize winners, advisors, partners, and collaborators across industries combine their impressive reach to create a single, powerful philanthropic amplification platform to awaken the hero in all of us. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook, Instagram, LinkedIn, and Twitter.

About MIT Solve

Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu .

Link:

ClickThru

Social Media:

https://www.facebook.com/ElevatePrize/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye